Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.

Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, Bash D, Hislop C.

Cardiovasc Drugs Ther. 2012 Feb;26(1):71-5. doi: 10.1007/s10557-011-6358-9.

PMID:
22109255
2.

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators..

JAMA. 2014 Jan 15;311(3):252-62. doi: 10.1001/jama.2013.282836.

PMID:
24247616
3.

Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.

Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D.

J Am Coll Cardiol. 2010 Sep 28;56(14):1079-88. doi: 10.1016/j.jacc.2010.06.015. Erratum in: J Am Coll Cardiol. 2011 Mar 29;57(13):1501.

4.

Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.

Rosenson RS, Fraser H, Goulder MA, Hislop C.

Cardiovasc Drugs Ther. 2011 Dec;25(6):539-44. doi: 10.1007/s10557-011-6344-2.

PMID:
21989792
5.

Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.

Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, Schwartz GG, Tsimikas S; Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Trial Investigators..

Circulation. 2012 Feb 14;125(6):757-66. doi: 10.1161/CIRCULATIONAHA.111.063487. Epub 2012 Jan 9.

6.

After FRANCIS: next steps in the clinical evaluation of varespladib methyl.

Rosenson RS.

Future Cardiol. 2011 Jan;7(1):11-8. doi: 10.2217/fca.10.118.

PMID:
21174506
7.

Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.

Rosenson RS, Elliott M, Stasiv Y, Hislop C; PLASMA II Investigators..

Eur Heart J. 2011 Apr;32(8):999-1005. doi: 10.1093/eurheartj/ehq374. Epub 2010 Nov 16.

PMID:
21081550
8.

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators..

JAMA. 2001 Apr 4;285(13):1711-8.

PMID:
11277825
9.

Varespladib.

[No authors listed]

Am J Cardiovasc Drugs. 2011;11(2):137-43. doi: 10.2165/11533650-000000000-00000. Review.

PMID:
21446779
10.
11.

Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?

O'Donoghue ML.

Nat Rev Cardiol. 2014 Mar;11(3):130-2. doi: 10.1038/nrcardio.2013.220. Epub 2014 Jan 14.

PMID:
24419257
12.

The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.

Džavík V, Lavi S, Thorpe K, Yip PM, Plante S, Ing D, Overgaard CB, Osten MD, Lan J, Robbins K, Miner SE, Horlick EM, Cantor WJ.

Circulation. 2010 Dec 7;122(23):2411-8. doi: 10.1161/CIRCULATIONAHA.110.950733. Epub 2010 Nov 22.

13.

Therapeutic Role of Innovative Anti-Inflammatory Medications in the Prevention of Acute Coronary Syndrome.

Pashun RA, Frishman WH.

Cardiol Rev. 2015 Sep-Oct;23(5):252-60. doi: 10.1097/CRD.0000000000000062. Review.

PMID:
25741604
14.

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators..

Circulation. 2003 Sep 30;108(13):1560-6. Epub 2003 Sep 15.

15.

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators..

Circulation. 2004 Jul 27;110(4):386-91. Epub 2004 Jul 19.

16.

Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators..

Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):142-7. Epub 2007 Nov 8.

18.

Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators..

Atherosclerosis. 2009 Oct;206(2):551-5. doi: 10.1016/j.atherosclerosis.2009.03.020. Epub 2009 Mar 26.

PMID:
19394618
19.

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.

PMID:
17910519
20.

Phospholipase A2 enzymes and the risk of atherosclerosis.

Rosenson RS, Hurt-Camejo E.

Eur Heart J. 2012 Dec;33(23):2899-909. doi: 10.1093/eurheartj/ehs148. Epub 2012 Jul 15. Review.

PMID:
22802388

Supplemental Content

Support Center